Welcome to our dedicated page for Curaleaf Hldgs SEC filings (Ticker: CURLF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Curaleaf Holdings, Inc. files foreign issuer reports that document its cannabis operations, financial statements, governance actions, and capital-structure matters. Recent Form 6-K filings include interim consolidated financial statements, management discussion and analysis, CEO and CFO certifications, press releases, and documents incorporated by reference into a Form F-10 registration statement.
The filing record covers auditor changes, annual and special meeting matters, director elections, auditor appointment, equity incentive plan items, multiple voting share provisions, subordinate voting shares, normal course issuer bid activity, automatic securities disposition plans, and completed acquisition disclosures for Four 20 Pharma.
Curaleaf Holdings, Inc. reports that Spain’s medicines regulator, AEMPS, has formally approved the registration of two standardized cannabis preparations, one THC‑dominant and one CBD‑dominant, developed by its Spanish manufacturing subsidiary. These registrations, listed as CAN‑1 and CAN‑2, are the first under Spain’s new medicinal cannabis framework, Royal Decree 903/2025, and clear the path for supply to hospital pharmacies for use in magistral formulas pursuant to medical prescription.
The milestone builds on Curaleaf’s EU‑GMP certified manufacturing facility and R&D laboratory in Alicante and on Medalchemy SL’s 2020 AEMPS license to process medicinal cannabis derivatives. Spain, a country of nearly 50 million people, is described as central to Curaleaf’s vision for Europe. The preparations are expected to become available to patients through hospital pharmacies in due course, in line with the new framework and subject to actions by Spanish health authorities.
Curaleaf Holdings, Inc. reported a capital-markets milestone: exchange-traded options on its subordinate voting shares are expected to begin trading on the Montréal Exchange on July 13, 2026 under the symbol CURA.
The listing is initiated solely by the Exchange and involves no new share issuance, no dilution, and no proceeds to Curaleaf. The company believes listed options may enhance liquidity and price discovery and expand investor tools for hedging, income, and directional strategies, particularly for institutional and derivatives-focused investors.
Curaleaf Holdings reports that its Subordinate Voting Shares have resumed trading under the OTCQX symbol CURLF, effective July 6, 2026. The shares had temporarily traded under CURLD for a 20-trading-day transition period following a previously announced 1-for-3 reverse stock split effective June 5, 2026.
The return to the original CURLF symbol is an administrative change and requires no action from shareholders. Curaleaf’s shares continue to trade on the Toronto Stock Exchange under the symbol CURA and on the OTCQX Best Market under CURLF, both under the post-split CUSIP 23126M300.
Curaleaf Holdings, Inc. will release its financial and operating results for the second quarter ended June 30, 2026 after market close on August 5, 2026. The company will host a conference call and webcast at 5:00 p.m. ET that day, followed by a Q&A session.
A replay will be available by dial-in through August 12, 2026. Curaleaf describes itself as a leading international provider of cannabis consumer products, operating well-known brands across medical and adult-use markets in North America and Europe and listing its shares on the Toronto Stock Exchange and OTCQX.
Curaleaf Holdings reported results of its 2026 annual general and special shareholders meeting, where 1.71 billion votes were cast. Shareholders approved an amendment to the articles removing the automatic conversion feature of the Company’s Multiple Voting Shares after a U.S. stock exchange listing, with strong support across all voting classes.
They also approved an exchange program under which up to 10,070,478 stock options with exercise prices or performance conditions at or above US$5.00 can be exchanged for restricted share units under the 2018 Stock and Incentive Plan. In addition, shareholders backed a plan of arrangement to continue the Company from British Columbia to the State of Delaware, subject to court approval.
All seven nominated directors were elected with more than 97% support each, BDO USA, P.C. was reappointed as auditor, and shareholders approved continued use of the long-term incentive plan and related unallocated awards.
Curaleaf Holdings has filed a supplement to its management information circular ahead of its June 22, 2026 annual and special meeting. Shareholders are being asked to approve an amendment to the Company’s articles that would remove the automatic conversion trigger tied to a future U.S. stock exchange listing for multiple voting shares held by CEO and Chairman Boris Jordan, preserving the dual-class structure beyond any such listing.
The Board approved the amendment by majority, with one director opposing on the basis that it was not necessary and could have led to an unfavorable market reaction; the Company notes there was no discernible reaction after the announcement. A Special Committee reviewed alternatives, confirmed retained ownership-based sunsets and MI 61-101 “majority of the minority” protections, and chose not to hire separate legal counsel. Curaleaf also extends the proxy cut-off so shareholders can vote their Subordinate Voting Shares up to 3:00 p.m. Eastern time on June 19, 2026.
Curaleaf Holdings, Inc. has implemented a reverse stock split of its subordinate voting shares, converting three pre-split shares into one post-split share. The change took effect at the start of trading on June 5, 2026, after board approval.
The company also consolidated its multiple voting shares at the same three-to-one ratio to keep the relative rights between share classes unchanged. Subordinate voting shares outstanding moved from 698,731,895 pre-split to approximately 232,910,632 post-split, with fractional shares rounded up or down to the nearest whole share.
Curaleaf Holdings, Inc. is implementing a previously announced 1-for-3 reverse stock split of its subordinate voting shares, effective June 5, 2026. After the split, subordinate voting shares will continue to trade on the TSX under the symbol CURA with a new CUSIP number 23126M300.
The company currently has 698,731,895 subordinate voting shares outstanding, which is expected to become approximately 232,910,632 shares after the split. Fractional shares will not be issued; amounts will be rounded to the nearest whole share. Multiple voting shares will be consolidated on the same 1-for-3 basis to preserve relative rights.
Curaleaf Holdings, Inc. plans a 1-for-3 reverse stock split of its subordinate voting shares, expected to take effect on or about June 5, 2026, after receiving conditional approval from the Toronto Stock Exchange. Each three pre-consolidation shares will become one post-consolidation share, which is expected to reduce the number of issued and outstanding subordinate voting shares from 698,728,008 to approximately 232,909,336.
The company explains that this move is intended to raise the trading price per share to meet share price criteria of major U.S. stock exchanges and align with limits used by some retail brokerage firms, supporting potential future uplisting and broader institutional investor participation. Fractional shares will not be issued; holdings will be rounded to the nearest whole share, and option and convertible security terms will be proportionately adjusted.
Curaleaf Holdings, Inc. is changing its independent auditor. At the company’s request, PKF O’Connor Davies, LLP will resign as auditor effective May 6, 2026, and BDO USA, P.C. will be appointed as the new auditor until the close of the next annual shareholders’ meeting.
The board of directors approved both the resignation and the appointment. Curaleaf states that the former auditor did not issue any modified opinions for the two most recently completed fiscal years or subsequent periods, and the board believes no “reportable event” under National Instrument 51-102 has occurred. Both PKF O’Connor Davies and BDO USA have provided letters agreeing with the company’s Notice of Change of Auditor.